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Recurrences of cervical cancer after definitive radiotherapy often occur at common iliac or para-aortic lymph nodes
as marginal lymph node recurrences. Patients with these recurrences have a chance of long-term survival by
optimal re-treatment with radiotherapy. However, the re-irradiation often overlaps the initial and the secondary
radiotherapy fields and can result in increased normal tissue toxicities in the bowels or the stomach. Carbon-ion
radiotherapy, a form of particle beam radiotherapy using accelerated carbon ions, offers more conformal and sharp
dose distribution than X-ray radiotherapy. Therefore, this approach enables the delivery of high radiation doses to
the target while sparing its surrounding normal tissues. Marginal lymph node recurrences in common iliac lymph
nodes after radiotherapy were treated successfully by carbon-ion radiotherapy in two patients. These two patients
were initially treated with a combination of external beam radiotherapy and intracavitary and interstitial
brachytherapy. However, the diseases recurred in the lymph nodes near the border of the initial radiotherapy fields
after 22 months and 23 months. Because re-irradiation with X-ray radiotherapy may deliver high doses to a section
of the bowels, carbon-ion radiotherapy was selected to treat the lymph node recurrences. A total dose of 48 Gy
(RBE) in 12 fractions over 3 weeks was given to the lymph node recurrences, and the tumors disappeared
completely with no severe acute toxicities. The two patients showed no evidence of disease for 75 months and
63 months after the initial radiotherapy and for 50 months and 37 months after the carbon-ion radiotherapy,
respectively. No severe late adverse effects are observed in these patients. The two presented cases suggest that
the highly conformal dose distribution of carbon-ion radiotherapy may be beneficial in the treatment of marginal
lymph node recurrences after radiotherapy. In addition, the higher biological effect of carbon-ion radiotherapy and
its superior dose distribution may provide more effective tumor control in treatment for re-irradiation of the
marginal recurrences in radiation resistant tumors other than cervical cancer.
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Metastases in common iliac or para-aortic lymph nodes
(LN) often occur after definitive radiotherapy (RT) for
cervical cancer [1]. RT for these lymph node metastases
provides a chance of long-term survival in these patients
[2]. However, if the recurrences occur very close to the
edge of the initially treated field after RT, there is a con-
cern that an overlap of the initial and the second* Correspondence: tamakit@gunma-u.ac.jp
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reproduction in any medium, provided the orradiation fields could yield a high cumulative dose and
possibly result in severe toxicities in normal tissues such
as the bowel. Carbon-ion RT, a form of particle beam
RT using accelerated carbon ions, offers more conformal
radiation dose distribution than X-ray RT and thus en-
ables the delivery of high radiation doses to the tumor
while sparing the surrounding normal tissues [3,4].
Carbon-ion RT has shown excellent local control for X-
ray resistant diseases such as recurrent rectal carcinoma,
skull-base tumors, uveal melanoma, non-squamous cell
carcinomas of the head and neck, and sarcomas. In these
tumors, high radiation doses could be delivered to theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complications in the surrounding normal organs [3,4].
In this article, we report two cases of recurrent cervical
cancer in the LN marginal to the RT fields utilized in the
initial treatment. Definitive carbon-ion RT was applied suc-
cessfully to the marginal LN recurrences of these patients
without further recurrences or severe complications.
Case presentation
Patient 1
A 55-year-old female presented with abnormal vaginal
bleeding and was diagnosed with FIGO Stage IIA
(T2aN0M0, UICC 6th edition) squamous cell carcinoma
of the uterine cervix. The patient had an elevated value
of serum squamous cell carcinoma antigen (SCC),
5.3 ng/ml (normal value: 0–1.5 ng/ml). The patient was
treated with external beam RT (EBRT) of 50 Gy in 25
fractions to the pelvis using conventional X-rays
(consisting of 26 Gy of whole pelvis fields and the last
24 Gy of center shielding pelvis fields) and 4 fractions of
high-dose-rate (HDR) intracavitary brachytherapy (BT)
with the total dose of 24 Gy given to point A. There
were no acute adverse effects greater than Grade 3.
However, there were Grade 2 upper gastrointestinal
symptoms and Grade 1 neutropenia. The tumor com-
pletely disappeared, and the serum SCC levels returned
to normal after therapy. Therefore, the patient received
no further treatment. Twenty-three months later, the pa-
tient developed bilateral edema in the legs. A contrast-
enhanced computed tomography (CT) study showed an
enlarged left common iliac LN with a diameter of 2 cm
situated at the edge of the previous whole pelvis irradi-
ation field (Figure 1(a)). Based on an elevated uptake of
18F-fluorodeoxy glucose (FDG) in the positron-emission
tomography (PET)/CT study (maximum SUV 6.1) andFigure 1 Location of the lymph node recurrences in relation to the ra
were reconstructed with red lines, while the recurred lymph nodes were co
radiation field both in (a) Patient 1 and (b) Patient 2.an elevated value of serum SCC (4.0 ng/ml), the en-
larged LN was clinically diagnosed as a metastasis of
cervical cancer. To avoid normal tissue complications
from re-irradiation, carbon-ion RT was selected as the
treatment modality. Carbon-ion RT (48 Gy (RBE) in 12
fractions over 3 weeks) was administered to the left
common iliac LN and the lower para-aortic LN (PALN)
region (Figure 2a). The patient experienced no serious
adverse effects during the therapy, and no further ther-
apy was administered. The serum SCC level returned to
normal levels (<1.0 ng/ml) after the carbon-ion RT treat-
ment. The patient showed no evidence of disease for
75 months after the initial RT and for 50 months after
the carbon-ion RT of the LN recurrence (Figure 3).
There were no serious adverse effects beside the leg
edema that was present prior to treatment.
Patient 2
A 52-year-old female patient presented with abnormal
vaginal bleeding and was diagnosed with squamous cell
carcinoma of uterine cervix. She was referred to our de-
partment for concurrent chemoradiotherapy. A colonos-
copy confirmed the invasion of the tumor into the rectal
mucosa, and the patient was staged to be FIGO Stage
IVA (T4N0M0, UICC 6th edition). The patient was
treated with EBRT of 50 Gy in 25 fractions to the pelvis
using conventional X-rays (consisting of 30 Gy of whole
pelvis fields and 20 Gy of center shielding pelvis fields)
and 5 fractions of HDR BT (2 fractions of intracavitary
BT with 6 Gy prescribed to the point A and 3 fractions
of image-guided interstitial BT with 6 Gy prescribed to
the gross tumor). The patient also received 4 courses of
weekly cisplatin at a dose of 40 mg/m2. Although Grade
2 upper gastrointestinal symptoms and leukopenia were
observed during the treatment, the tumor disappeareddiation field of the initial radiotherapy. The initial radiation fields
ntoured as red solids. Lymph nodes recurred at the edge of the initial
Figure 2 Comparison of carbon-ion radiotherapy (RT) and X-ray RT dose distributions in Patient 1. (a) Dose distribution of the carbon-ion
RT applied in Patient 1 for the lymph node (LN) recurrence. Carbon-ion RT of 48 Gy (RBE)/12 fractions/3 weeks was given to the left common
iliac LN and the lower para-aortic LN region at the National Institute of Radiological Sciences, Chiba, Japan. The isodose lines are shown by
percentage with respect to the total dose of 48 Gy (RBE). (b) Simulated dose distribution of X-ray (RT) using orthogonal 4 fields. The anterior-
posterior field of the initial RT is shown with thick red lines. The 50% isodose lines are highlighted in green.
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trast-enhanced CT and FDG-PET/CT showed an en-
larged PALN (10 mm in diameter, max SUV 3.10) and
an enlarged right common iliac LN (10 mm in diameter,
max SUV 2.81) at the edge of the whole pelvis irradi-
ation field utilized in the initial treatment (Figure 1(b)).
These lymph nodes were clinically diagnosed as metasta-
ses of cervical cancer. Similar to the previous patient,
carbon-ion RT with the dose of 48 Gy (RBE) in 12 frac-
tions over 3 weeks was administered to the common
iliac LN and lower PALN regions. The patient wasFigure 3 CT images of the recurred lymph nodes (LNs) at the time of
ion radiotherapy ((b) Patient 1, (d) Patient 2). The recurrent LNs have ddischarged with no apparent acute adverse effects. No
further therapy was administered, and the patient
showed no evidence of further recurrences for 63 months
after the initial RT and for 37 months after the carbon-
ion RT for the recurred LN (Figure 3). The patient expe-
rienced no late toxicities from the treatment.
Discussion
Metastases in the common iliac LN and PALN are often
observed after definitive RT for cervical cancers [1]. A
retrospective study of 1894 patients who receivedrecurrence ((a) Patient 1, (c) Patient 2)) and 3 years after carbon-
isappeared after the therapy in both patients.
Figure 4 Simulated diagram of cumulative dose distribution in
Patient 1. The dose distribution was simulated in a case if the re-
irradiation of 50 Gy were to be administered by 3D conformal X-ray
radiotherapy using an orthogonal 4-field technique. The cumulative
radiation dose to the bowels is greater than 70 Gy because of the
overlap of the initial and re-treatment radiation fields. The red lines
indicate the anterior-posterior field of the initial radiotherapy.
Tamaki et al. Radiation Oncology 2013, 8:79 Page 4 of 5
http://www.ro-journal.com/content/8/1/79definitive RT for cervical cancer at the M.D. Anderson
Cancer Center has shown that the most common site of
regional recurrence in patients with centrally controlled
disease was the cranial margin of the initial RT fields. In
the study, 198 patients (10.5%) had regional recurrences
with no central recurrence. Of these patients, 75 patients
(4.0%) were confirmed with diagnostic images to have only
marginal recurrences. Most of the recurrences were lo-
cated in the superior margin of the initial RT fields (73 pa-
tients) [1]. In other prospective clinical studies, the PALN
recurrences were observed in 7% of patients treated with
chemoradiotherapy in the Radiation Therapy Oncology
Group 90–01 trial [5]. Additionally, PALN recurrences
were found in 15% of patients in the Japanese Gynecologic
Oncology Group 1066 trial that studied patients with
more advanced diseases of FIGO Stage III-IV [6].
The 5-year overall survival of patients with solitary LN
metastases that are marginal to the initial radiation fields
was 13% in the M.D. Anderson Cancer Center study [1].
In contrast, it is reported that the 3-year and 5-year
overall survival of patients who received X-ray RT for
solitary PALN recurrence of cervical cancer were 50%
and 31%, respectively [2]. It was also found that the de-
livery of radiation doses above 50 Gy was a significantly
favorable factor for the survival of these patients [2].
These results indicate that patients with solitary recur-
rence in PALN or in the common iliac LN would be
candidates for definitive RT and could achieve long-term
survival if an adequate amount of radiation dose can be
safely delivered to the LN recurrence.
RT to the abdomen requires careful attention to pre-
vent adverse effects in the gastrointestinal tract, espe-
cially in the stomach and small bowels. The radiation
dose-volume analyses of normal tissue toxicities recom-
mend the volume of small bowels receiving doses above
45 Gy should be minimized [7]. To prevent the inci-
dence of severe normal tissue toxicities in cases of
re-irradiation, physicians should avoid or minimize the
volume receiving a high cumulative dose due to the
overlap of the initial and re-treatment irradiation fields.
In our simulation study of re-irradiation using conven-
tional X-ray treatment by 3D conformal RT, a strip of
small bowel is exposed to a cumulative irradiation dose
above 70 Gy (Figure 4) due to the overlap of radiation
fields. Thus, re-irradiation with X-ray RT could result in
a significant risk of complications in small bowels.
Alternatively, carbon-ion RT has been shown to have
higher anti-tumor effects and superior dose distributions
compared to conventional X-ray RT [3,4,8]. The superior
dose distribution of carbon ion beams results from the
ability of accelerated carbon ions to release a maximal
amount of energy at the end of the track as a so-called
Bragg peak. This energy release allows a smaller amount
of lateral scattering (penumbra) due to the greater massof carbon nuclei [3,4]. Due to the differences of treat-
ment planning systems between the carbon-ion RT and
X-ray RT, there is a limitation in the graphical presenta-
tion of cumulative dose distributions of these patients.
However, while the overlap of the treatment fields could
not be completely avoided, the application of carbon-ion
RT could significantly reduce the volume of small bowel
receiving high doses (Figure 2). As a result, the patients
did not have severe late toxicities. A possible uncertainty
in carbon-ion RT applied to abdomen is that its dose
distribution can be affected by the excessive fluctuation
of bowel gas in the beam track. In order to minimize
such uncertainty, the presence of bowel gas is checked
with daily fluoroscopic images used for patient set-up.
The two patients will continue to be followed carefully
and the incidence of late toxicities will be monitored.
These cases support previous reports that suggested
patients with marginal LN recurrences after definitive
RT of cervical cancers can possibly achieve long-term
survival if enough radiation is delivered to the target.
Carbon-ion RT is one of the modalities that may enable
re-irradiation for these patients in a safer manner.
Conclusions
In summary, in two patients with solitary marginal LN
recurrences after definitive RT, carbon-ion RT was suc-
cessfully applied to the lesions while minimizing high
doses to the bowels. The patients are disease free and do
not have late toxicities. Carbon-ion RT may be an
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ginal recurrences of cervical cancer and other malignant
tumors.
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